Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has engaged Fortrea as the contract research organisation (CRO) to manage the IND opening Phase 2/3 clinical trial investigating the company’s IHL-42X for the treatment of Obstructive Sleep Apnoea (OSA). This Phase 2/3 clinical trial will assess the safety and efficacy of IHL-42X in people with OSA who are intolerant, non-compliant or naïve to continuous positive airway pressure (CPAP).
Latham said, “The initial Phase 2 proof of concept clinical trial over IHL-42X demonstrated an average reduction in our primary end point, AHI of 50.7%, with 25% of subjects having a reduced AHI of >80%.
"Importantly, we also observed a reduction in average patient oxygen desaturation index of 59.7%, markedly improved sleep quality and a reduction in cardiovascular stress.
"These results were truly remarkable and now allow for this Phase 2/3 trial to be a genuine long-term safety and efficacy trial.
"If we again observe such remarkable drug efficacy, safely administered over the 52 weeks, Incannex is confident that our product will be marketable."
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
